To bring key stakeholders (HCPs, pharmaceutical and biotech companies, associations and advocacy groups) together for the common purpose of providing accurate and relevant information to the broader oncology community about the importance of testing and biomarker identification, and how to utilize biomarker status to inform treatment decisions.

To emphasize the importance of biomarker testing, comprehensive genomic profiling, and identification of actionable targets across disease states.

To improve:

• Testing frequency and the understanding of biomarker tests and therapeutic options
• Understanding and reading of biomarker reports
• Turnaround times for test results
• Access and equity in molecular testing